Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-aminopenicillanic acid is a small molecule β-lactam containing organic acid that serves as the **core chemical structure of all penicillin antibiotics**. It consists of a fused β-lactam-thiazolidine ring system with an amino group at position 6. Industrially, it is derived from penicillin G through enzymatic cleavage (penicillin acylases), providing the nucleus for generating semisynthetic penicillins (such as ampicillin, amoxicillin, oxacillin, carbenicillin, etc.) by substitution at the 6-amino position[1][3][7][12]. **Mechanism of action:** 6-aminopenicillanic acid itself retains the basic β-lactam mechanism—*it inhibits bacterial cell wall biosynthesis by binding and inactivating DD-transpeptidase enzymes (penicillin-binding proteins, PBPs), blocking cross-linking of peptidoglycan, leading to cell lysis and death*. However, by itself, 6-APA's antimicrobial spectrum is limited and it is primarily used as a pharmaceutical intermediate, not a finished drug[3][7][8]. Its chemical similarity to the D-Ala-D-Ala terminus of the cell wall precursors confers its mode of binding[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-aminopenicillanic acid.